SEC Info - Prestwick Pharmaceuticals Inc - IPO: ‘S-1’ on 4/22/05

SEC Info℠

Home

Help

Please Sign In

Prestwick Pharmaceuticals Inc – IPO: ‘S-1’ on 4/22/05 – EX-23.2

On: Friday, 4/22/05, at 5:32pm ET · Accession #: 950133-5-1662 · File #: 333-124276

  As Of                Filer                Filing    For·On·As Docs:Size              Issuer               Agent

 4/22/05  Prestwick Pharmaceuticals Inc     S-1                   23:3.4M                                   Bowne - DC/FA

Initial Public Offering (IPO): Registration Statement (General Form) — Form S-1
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: S-1         Form S-1 Prestwick Pharmaceuticals, Inc.            HTML   1.18M 
 2: EX-3.1      Form of Amended and Restated Certificate of         HTML     24K 
                          Incorporation                                          
 3: EX-3.2      Amended and Restated Bylaws                         HTML    128K 
 4: EX-4.2      Amended and Restated Investor Rights Agreement      HTML    190K 
 9: EX-10.10    Amended and Restated Agreement -- Cambridge         HTML    187K 
                          Laboratories                                           
10: EX-10.11    Agreement Dated February 2, 2004                    HTML     51K 
11: EX-10.12    Development and Commercialization License and       HTML    268K 
                          Clinical Supply Agreement                              
12: EX-10.13    License Agreement -- Dr. Maurice W. Gittos          HTML     78K 
13: EX-10.14    License Agreement -- the General Hospital           HTML     75K 
                          Corporation                                            
14: EX-10.15    Letter Agreement -- Melvin D. Booth                 HTML     29K 
15: EX-10.16    Letter Agreement -- David A. Cory                   HTML     25K 
16: EX-10.17    Letter Agreement -- Christopher F. O'Brien          HTML     25K 
17: EX-10.18    Letter Agreement -- James P. Shaffer                HTML     23K 
18: EX-10.19    Letter Agreement -- William H Washecka              HTML     22K 
19: EX-10.20    Letter Agreement -- Benjamin P. Lewis               HTML     18K 
20: EX-10.21    Separation Agreement -- Robert S. Whitehead         HTML     65K 
21: EX-10.22    Letter Agreement -- Mark Van Ausdal                 HTML     66K 
 5: EX-10.5     Form of Indemnification Agreement                   HTML     72K 
 6: EX-10.6     Asset Purchase and Subscription Agreement           HTML    188K 
 7: EX-10.7     Executive Employment Agreement - Kathleen           HTML     54K 
                          Clarence-Smith, M.D., Ph.D.                            
 8: EX-10.9     Agreement for Canadian Rights to Nitoman            HTML    204K 
22: EX-21.1     Subsidiaries of the Registrant                      HTML      8K 
23: EX-23.2     Consent of Experts or Counsel                       HTML      9K

EX-23.2 — Consent of Experts or Counsel

This exhibit is an HTML Document rendered as filed. [ Alternative Formats ]

exv23w2

Exhibit 23.2

Consent of Independent Registered Public Accounting Firm

We consent to the reference to our firm under the caption “Experts” and to the use of our reports dated April 19, 2005, in the Registration Statement (Form S-1 No. 333- ) and related Prospectus of Prestwick Pharmaceuticals, Inc. for the registration of shares of its common stock.

/s/ Ernst & Young LLP

McLean, Virginia
April 21, 2005

Dates Referenced Herein

This ‘S-1’ Filing	Date	Other Filings

Filed on:	4/22/05	None on these Dates
	4/21/05
	4/19/05
		List all Filings

↑Top

Filing Submission 0000950133-05-001662 – Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)